Zepbound Prior Authorization Criteria for Weight Loss

The list price of Zepbound in the US is approximately $1,086.37 per month, making it an expensive option for weight loss treatment. While insurance may help reduce the cost, many patients must first go through a prior authorization (PA) process to get coverage.

A 2021 study on prior authorization’s impact on gastroenterology practice highlighted the administrative burden, resource strain, and potential harm to patient care caused by PA requirements. Alarmingly, 50% of surveyed healthcare professionals reported cases where PA-related delays led to serious health risks for patients.

This article will break down the Zepbound prior authorization criteria, explaining what insurers typically require, how to improve your chances of approval, and steps to minimize delays.

General Prior Authorization Requirements

Nearly all US insurance providers require prior authorization (PA) for Zepbound due to its cost and specific approved use. In a PA, the insurer asks the prescriber to prove that the drug is medically necessary and that the patient meets certain criteria.

In practice, this means your healthcare provider must submit documentation of your diagnosis of obesity, relevant health history, and treatment plan. Insurers expect to see that you’ll use Zepbound as the FDA intends–specifically, as an addition to a reduced-calorie diet and increased physical activity for weight management.

To successfully submit a PA, you need to clearly demonstrate that you meet all coverage criteria and that you’re using Zepbound in accordance with clinical guidelines.

Zepbound Prior Authorization Criteria for Obesity

When filing a PA request, your doctor will typically need to provide key details, including:

1. BMI and Comorbidities

Most insurance plans follow the same fundamental eligibility criteria for Zepbound. You may qualify if you have either:

• • A BMI of 30 or higher (classified as obesity), or
  • A BMI of at least 27 along with one or more weight-related health conditions.

These requirements align with the FDA-approved indication for anti-obesity medications. If your BMI falls between 27 and 29.9, you will only meet the criteria if you also have a significant obesity-related condition.

Common qualifying conditions include:

• • Type 2 diabetes
  • High blood pressure (hypertension)
  • High cholesterol or abnormal lipid levels (dyslipidemia)
  • Obstructive sleep apnea
  • Other serious health issues worsened by obesity

For example, if your BMI is 28, your insurer may approve Zepbound only if you also have a condition like hypertension or type 2 diabetes that justifies the need for treatment. However, if your BMI is 30 or higher, you generally qualify based on obesity alone.

These BMI and health condition criteria are consistent across insurance PA policies.

2. Lifestyle Intervention

Beyond BMI, insurers typically require proof that you have attempted other weight-loss methods before starting medication. Most PA criteria include documentation of a trial period, often 3, 6, or 12 months, of structured diet and exercise before approving Zepbound.

Your physician may need to confirm (and provide medical records) that you participated in a weight management program but did not achieve significant weight loss. This may involve:

• • Nutritional counseling
  • Exercise programs (unless a medical condition prevents physical activity)
  • Behavioral changes

Your medical records should include details on your adherence to a structured dietary plan, often requiring a daily 500-calorie deficit, and an exercise regimen of at least 150 minutes of physical activity per week. This ensures that Zepbound is being prescribed as a next step, rather than a first-line treatment.

3. Step Therapy

Some insurers require step therapy, meaning you may need to try and fail at least one other weight-loss medication before they approve Zepbound. In many cases, this means first attempting a non-GLP-1 weight-loss drug, such as:

• • Phentermine
  • Orlistat
  • Naltrexone/bupropion
  • Phentermine/topiramate
  • Other similar therapies

If you are unable to tolerate non-GLP-1 weight-loss medications, your insurer may ensure that you are not already taking another GLP-1 medication.

For example, Aetna Medicare Better Health’s plan considers a medication trial unsuccessful if:

• • Benzphetamine, diethylpropion, phendimetrazine, or phentermine: You do not lose at least 10 lbs after three months.

• • Orlistat: You do not lose 10 lbs after six months.

• • GLP-1 receptor agonists (Saxenda): You do not achieve at least a 5% reduction in body weight after six months.

If these previous treatments were ineffective or caused intolerable side effects, you may be eligible to move up to Zepbound.

4. Other Eligibility Factors

Your insurer may also enforce additional safety and appropriateness requirements, such as:

• • Age Requirement: Zepbound is only approved for adults, so you generally must be at least 18 years old.

• • Medical History: You should not have a history of an eating disorder, including anorexia or bulimia. Additionally, if you or a family member has a history of medullary thyroid carcinoma or MEN2 syndrome, Zepbound may not be an option due to safety concerns associated with GLP-1 medications.

• • Pregnancy Considerations: If you are pregnant or planning to become pregnant, certain insurers (particularly state-funded programs) may require confirmation that your obesity is significantly affecting your health to justify medical treatment.

Your doctor will also need to submit a copy of your current weight-loss plan. This documentation should include your latest height and weight measurements, ensuring that the PA request meets all necessary criteria.

Zepbound Prior Authorization Criteria by Major Insurer

Below are the specific requirements set by major insurers.

Medicare (Medicare Part D and Advantage)

Due to a statutory exclusion, Medicare has historically not covered weight-loss medications when used solely to treat obesity. If you are on a Medicare Part D plan, a prior authorization for Zepbound would generally be denied if obesity is the only indication.

The good news is that the Centers for Medicare & Medicaid Services (CMS) confirmed that following the FDA’s approval of Zepbound for obstructive sleep apnea (OSA) in December 2024, Medicare Part D plans can now cover this medication for that specific condition.

This means that if you have a serious comorbidity like OSA, your doctor should list it as the primary diagnosis and obesity as secondary when submitting documentation.

Keep in mind that Zepbound’s prior authorization criteria for OSA are different and may require step therapy, such as positive airway pressure (PAP) therapy and stimulants, before approval. Unless and until Medicare policy changes, you will likely have to pay out of pocket for Zepbound.

Medicaid

Medicaid coverage for Zepbound varies widely by state, since state Medicaid programs are allowed (but not required) to cover weight-loss medications. As of late 2024, only about 13 state Medicaid programs cover GLP-1 agonists for obesity treatment on their formularies.

These include:

1. 1. California
   2. Kansas
   3. Minnesota
   4. Wisconsin
   5. Michigan
   6. Mississippi
   7. Pennsylvania
   8. Virginia
   9. North Carolina
   10. Massachusetts
   11. New Hampshire
   12. Delaware
   13. Rhode Island

State Medicaid policies generally follow standard requirements but often demand extensive documentation. Your doctor may need to submit details such as your current weight, BMI, weight trend, and weight-loss plan. They may also need to confirm that your obesity is causing severe health issues.

For example, Virginia’s Medicaid dual plan prior authorization form requires your prescriber to attest that your obesity is “disabling and life-threatening.”

Aetna (Commercial Insurance)

Aetna’s clinical policy for weight-loss medications follows the standard obesity requirements.

Aetna also includes continuation criteria. After your initial course of therapy is approved, you will only receive extended coverage if you demonstrate meaningful weight reduction.

Specifically, after about three months on Zepbound at a stable maintenance dose, you must have lost at least 5% of your baseline body weight (or maintained at least a 5% loss if you had already lost weight on a prior medication). Aetna requires documentation of this weight loss to approve continued therapy beyond that point.

Blue Cross Blue Shield (Commercial Insurance)

Blue Cross Blue Shield (BCBS) plans, often operated regionally (e.g., Anthem, local BCBS companies), generally follow similar prior authorization requirements for weight-loss medications.

For example, BCBS of Massachusetts grants initial approval for Zepbound for up to six months. After this period, your doctor must submit an update for renewal. To qualify, you must have lost at least 5% of your starting weight in the first 20 weeks, be continuing to lose weight, or have maintained 5% loss if your weight has plateaued.

If you meet this requirement and tolerate Zepbound at a maintenance dose (5 mg, 10 mg, or 15 mg, as per the medication’s dosing schedule), BCBS may approve an additional 12 months of therapy.

Process for Obtaining Prior Authorization for Zepbound

Getting prior authorization for Zepbound involves several steps that you and your doctor must navigate.

1. Verify Coverage and Criteria

The first step is to check whether your insurance plan covers Zepbound and, if so, what the specific PA requirements are. You or your doctor can call your insurance company or review your plan’s formulary document to see if Zepbound is listed and marked as requiring prior authorization.

Knowing these requirements in advance helps your doctor gather the necessary information. If Zepbound isn’t on the formulary (i.e., “not covered”), your doctor may discuss filing a formulary exception or explore whether an alternative medication is covered.

2. Gather Medical Information

Next, your doctor will collect all the necessary details to support your PA request. This includes documenting your height, weight, BMI, obesity diagnosis (with the appropriate ICD-10 code, such as E66.01 for morbid obesity), and any related health conditions (with their respective codes).

Your doctor should also document previous weight-loss efforts, such as:

• • “Tried lifestyle changes for six months, lost only three lbs.”

• • “Previously tried phentermine for three months without significant weight loss.”

It’s also vital to document any comorbid conditions you have, as these strengthen the medical necessity of treating obesity. The more comprehensive this information is, the stronger your PA submission will be.

3. Submission of the PA Request

Your doctor will then fill out the insurer’s Zepbound prior authorization form or submit the request electronically. Many insurers use electronic prior authorization systems through electronic health records or web portals, while others may require a faxed PA form specific to Zepbound.

Supporting documents such as recent progress notes, weigh-in records, and lab results are often required. Including these can help prevent delays, as insurers typically need proof beyond just checkboxes on a form.

Once completed, your PA request is submitted to the insurance plan’s pharmacy benefits manager (PBM) for review.

4. Wait for Determination

After submission, your insurance plan will review the PA request and issue a decision. The processing time can vary. Some approvals happen within minutes or hours if the system is automated and all criteria are clearly met, while others may take a few days.

By law, Medicare Part D and many commercial plans must respond to a standard PA request within a few business days (typically 72 hours), or faster if it’s considered urgent. In practice, many PA decisions are made within one to five days.

For more complex cases, especially if additional information is required, the process might take up to a couple of weeks.

5. Approval

If your PA is approved, your insurance plan will cover Zepbound under the specified terms. The approval often includes a set duration and/or quantity limit. For example, the approval might state that you are authorized to receive Zepbound for six months, with up to four pens per 28 days.

You can then fill your prescription at the pharmacy with your insurance covering its share.

Note!

It’s important to continue following the agreed-upon weight-loss plan (such as maintaining diet and exercise changes and scheduling follow-ups) since proof of progress will be required for renewal.

Your doctor should also document your weight loss over the initial treatment period in preparation for a renewal PA. Before your approval period expires, your doctor will likely need to submit a re-authorization request with updated details, including how much weight you’ve lost on Zepbound.

As noted earlier, many insurers require you to lose at least 5% of your starting weight to qualify for continued coverage. If you meet this requirement, your PA can typically be renewed for six to twelve months at a time.

Steps to Take if a Prior Authorization is Denied (Appeals Process)

If your Zepbound prior authorization request is denied, you can appeal the decision. An appeal is your opportunity to request that your insurer reconsider and overturn the denial, typically by providing additional justification for why the medication is medically necessary.

Here’s what you need to do:

1. Review the Denial Notice

Once your PA is denied, your insurance plan will send a notification, often called an Explanation of Benefits (EOB) or denial letter, explaining why. The reason may be specific, such as:

• • “Coverage denied because BMI is below the required threshold.”

• • “Denied due to lack of evidence of prior therapy.”

• • “Drug not covered for weight loss on this plan.”

Understanding the exact reason for the denial is essential. Sometimes, it’s due to an administrative issue, such as missing information, which can often be fixed with a correction or re-submission. Other times, the denial occurs because you didn’t meet a specific requirement.

If the issue is missing documentation or a misunderstanding, your doctor can often re-submit the request with the necessary information. For example, if your doctor forgot to attach records proving a six-month diet attempt, submitting those on appeal may resolve the issue.

2. Initiate an Appeal (Internal Appeal)

The first level of appeal is usually an internal appeal, where your insurer reviews your case again, this time with any new information or a fresh review by a different person.

Your denial letter will include instructions on how to file an appeal, along with the deadline (often 60 to 180 days for private insurance; Medicare Advantage/Part D appeals have their own specific timeframes).

You should work with your doctor to prepare your appeal. This often involves submitting a letter of medical necessity or an appeal letter explaining why Zepbound is needed and directly addressing the reason for the denial.

To strengthen your case, include additional medical documentation, such as:

• • Specialist notes supporting your need for treatment.
  • A more detailed weight history showing past attempts at weight loss.
  • Evidence of previous treatments (e.g., failed trials of other medications).

This is your second chance to prove that you meet the intent of the coverage policy.

3. Consider a Peer-to-Peer or Exceptions (if available)

If your appeal is still under review, your doctor may have the option to request a peer-to-peer review with the insurance company’s medical reviewer.

This is a phone discussion between your doctor and an insurance company physician or pharmacist, where they can clarify the case and provide additional justification.

While this is not a formal appeal, it can sometimes lead to an overturned denial or help determine what additional evidence is needed to secure approval.

4. External or Second-Level Appeals

If your internal appeal is denied, you may have the option to pursue a second-level appeal. Many insurance plans allow for an external review by an independent third party (such as a state insurance commission or external review organization) once internal appeals are exhausted.

If you are covered under Medicare, you have access to a structured appeals process with multiple levels, including:

• • Redetermination
  • Reconsideration by an Independent Review Entity
  • Administrative Law Judge hearing (for Medicare Part D or Advantage denials)

At each appeal stage, be sure to submit any new supporting evidence and restate your case for medical necessity.

It’s worth noting that appeals often succeed. According to a US Government Accountability Office study, between 39% and 59% of internal appeals result in the insurer reversing their original denial.

How to Request an External Review Through the HHS Federal Process

Every state is required to provide an external review process that aligns with federal regulations. The HHS Federal Process, managed by the Department of Health and Human Services (HHS), is available at no cost. However, some state-run or independent review systems may impose a fee, which is capped at $25.

If you wish to request an external review through the Federal process:

• • Online: Visit externalappeal.cms.gov
  • Phone: Call 1-888-866-6205 to request a form
  • Fax: Send to 1-888-866-6190
  • Mail: Send to MAXIMUS Federal Services, Pittsford, NY
  • Email: Use ferp@maximus.com

5. Explore Alternatives if Final Denial Occurs

If you’ve gone through all appeal options and the denial remains, you may need to explore alternative solutions. These can include:

• • Paying out-of-pocket for the medication
  • Switching to a covered alternative like Wegovy or Saxenda
  • Changing your insurance plan during the next enrollment period to one that includes obesity treatment coverage

In some cases, people turn to clinical trials or other programs to access expensive medications when insurance won’t cover them.

It’s also a good idea to stay informed about new insurance policies or legislative changes. For instance, if you’re on Medicare, you may want to watch for potential policy updates that could expand coverage for obesity medications in the future.

You need to remain persistent, gather strong evidence, and follow each step in the appeals process to maximize your chances of overturning the denial.

Financial Assistance Programs for Zepbound

If you’re looking for ways to reduce the cost of Zepbound, several financial assistance options are available. These include:

Eli Lilly’s Zepbound Savings Card (Co-pay Coupon)

Eli Lilly, the manufacturer of Zepbound, offers a Savings Card program to help commercially insured individuals lower their co-pays. If you qualify, you may pay as little as $25 for a one-month or three-month supply of Zepbound pens.

Here’s what you need to know:

• • If your commercial insurance covers Zepbound: You may pay as little as $25 per month, with your insurer covering the rest and Lilly paying up to the program’s limit.

• • If your commercial insurance denies coverage: You can still use the savings card to reduce the out-of-pocket cost to around $650 for four pens.

• • Not available if you have Medicare, Medicaid, or other government insurance programs.

These offers often expire or require annual reactivation, and the terms can change. As of early 2025, Lilly’s Zepbound Savings Card remains one of the most generous programs for weight-loss medications, helping reduce costs while insurance coverage is still catching up.

Lilly Cares Patient Assistance Program (PAP)

Lilly Cares is a nonprofit foundation that provides free medications to those who qualify based on financial need. While Zepbound is not explicitly listed on the Lilly Cares website, the program typically covers most Eli Lilly medications for individuals who lack insurance or have limited coverage. Since tirzepatide (Zepbound’s active ingredient) is a Lilly product, you may be able to request assistance through this program.

To qualify, you generally need to:

• • Have no insurance (or be underinsured for the medication)
  • Meet income requirements set by Lilly Cares

If approved, you could receive Zepbound at no cost for up to 12 months, often delivered directly to your home or doctor’s office.

LillyDirect & Self-Pay Options

Eli Lilly also offers a self-pay option through LillyDirect Pharmacy Solutions. This isn’t traditional financial assistance (since it’s not free or insurance-based), but it provides a way to purchase Zepbound at a lower flat cash price.

LillyDirect is a mail-order pharmacy service that ships medications directly. For Zepbound, LillyDirect offers single-dose vials (instead of the pen injector) at the following prices:

• • $499 per month for 5 mg, 7.5 mg, or 10 mg dose vials
  • $349 per month for the 2.5 mg dose

This can be a more affordable option if you’re paying out of pocket.

Other Ways to Save

Beyond manufacturer programs, you may be able to find additional savings through:

• • Employer or State Employee Health Programs: Some large employers and state governments have started covering weight-loss medications as part of their health benefits.

• • Pharmacy Discount Programs: Using prescription discount cards or coupons (such as GoodRx or SingleCare) may help lower costs if you’re paying in cash. GoodRx, for example, sometimes reduces Zepbound prices to around $900-$1,000 per month, depending on the pharmacy. While still expensive, it’s lower than the full retail price.

• • Clinical Trials or Research Studies: If you qualify for a clinical trial, you may be able to receive Zepbound free of charge while participating in a study. These trials are often conducted at academic medical centers and focus on either new obesity medications or further research on existing drugs like tirzepatide.

• • Canadian Pharmacy Network: At Pharma Giant, an online platform that partners with licensed Canadian pharmacies, you can find Zepbound at significantly lower prices. We also offer coupons to help you save even more.

Staying informed about new savings programs and policy changes can help you find additional ways to afford your medication.

Summary

Getting prior authorization for Zepbound requires meeting specific insurance criteria, including BMI thresholds, documented comorbidities, and proof of prior weight-loss attempts. Some insurers also require trying other weight-loss medications first.

Coverage varies. Medicare has limited options, Medicaid depends on the state, and commercial insurers often require ongoing weight loss for continued approval. If PA request is denied, you can appeal by submitting additional medical documentation or requesting a review. Proper evidence can often make appeals successful.

For cost savings, Eli Lilly’s discount programs, pharmacy coupons, and Canadian pharmacy networks like Pharma Giant offer lower prices. Understanding these options can help you secure coverage or find affordable alternatives.

Frequently Asked Questions